Lilly To Cease Development of Phase III Alzheimer's Drug
The setback for semagacestat is yet another blow Lilly can ill afford as it aims to scale its patent cliff. It could also signal trouble for an entire class of related therapies.
The setback for semagacestat is yet another blow Lilly can ill afford as it aims to scale its patent cliff. It could also signal trouble for an entire class of related therapies.